Organogenesis (NASDAQ:ORGO) Stock Price Down 3.7% After Insider Selling

Organogenesis (NASDAQ:ORGO) shares dropped 3.7% on Friday following insider selling activity. The stock traded as low as $5.50 and last traded at $5.5550. Approximately 209,215 shares traded hands during trading, a decline of 86% from the average daily volume of 1,449,700 shares. The stock had previously closed at $5.77.

Specifically, Director Glenn H. Nussdorf sold 200,000 shares of the company’s stock in a transaction on Tuesday, December 16th. The shares were sold at an average price of $5.14, for a total value of $1,028,000.00. Following the transaction, the director directly owned 2,565,591 shares of the company’s stock, valued at approximately $13,187,137.74. This represents a 7.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on ORGO shares. Weiss Ratings reissued a “sell (d+)” rating on shares of Organogenesis in a research report on Monday, December 15th. Wall Street Zen raised Organogenesis from a “hold” rating to a “strong-buy” rating in a research note on Saturday, November 8th. Finally, BTIG Research reiterated a “buy” rating and set a $9.00 price target on shares of Organogenesis in a report on Monday, December 15th. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $8.00.

Organogenesis Price Performance

The company’s 50-day simple moving average is $4.88 and its 200 day simple moving average is $4.52. The company has a quick ratio of 2.88, a current ratio of 3.32 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $710.70 million, a price-to-earnings ratio of -46.67 and a beta of 1.47.

Organogenesis (NASDAQ:ORGO) last announced its quarterly earnings results on Thursday, November 6th. The company reported $0.18 earnings per share for the quarter, topping analysts’ consensus estimates of $0.07 by $0.11. The company had revenue of $150.86 million during the quarter, compared to analysts’ expectations of $134.10 million. Organogenesis had a positive return on equity of 4.01% and a negative net margin of 1.30%. Equities research analysts forecast that Organogenesis will post -0.07 EPS for the current year.

Institutional Investors Weigh In On Organogenesis

A number of large investors have recently added to or reduced their stakes in ORGO. Vanguard Group Inc. raised its position in shares of Organogenesis by 23.4% in the first quarter. Vanguard Group Inc. now owns 4,431,414 shares of the company’s stock valued at $19,144,000 after purchasing an additional 841,618 shares during the period. Invesco Ltd. boosted its holdings in shares of Organogenesis by 779.7% during the 1st quarter. Invesco Ltd. now owns 1,069,252 shares of the company’s stock worth $4,619,000 after buying an additional 947,705 shares during the period. Nuveen LLC bought a new stake in shares of Organogenesis during the 1st quarter worth $742,000. Russell Investments Group Ltd. acquired a new position in Organogenesis in the 1st quarter valued at $547,000. Finally, American Century Companies Inc. grew its stake in Organogenesis by 32.7% in the 1st quarter. American Century Companies Inc. now owns 131,220 shares of the company’s stock valued at $567,000 after buying an additional 32,328 shares during the last quarter. Institutional investors own 49.57% of the company’s stock.

About Organogenesis

Organogenesis Inc operates as a regenerative medicine company focused on the development, manufacturing and commercialization of therapeutic solutions for wound care, surgical repair and sports medicine. The company’s product portfolio addresses a range of acute and chronic tissue repair needs, leveraging bioengineered skin substitutes, human placental-derived products and other allografts designed to promote healing and reduce scarring. Organogenesis markets its therapies to hospitals, outpatient clinics, wound care centers and other healthcare providers.

Key offerings include Apligraf, a living skin substitute for treatment of diabetic foot ulcers and venous leg ulcers; Dermagraft, a cryopreserved human fibroblast-derived dermal substitute; Grafix, a placental membrane allograft for complex and chronic wounds; and TheraSkin, a cryopreserved human skin allograft used in surgical and reconstructive procedures.